Last reviewed · How we verify
Desmopressin Injectable Solution
Desmopressin is a synthetic vasopressin analog that binds to V2 receptors on kidney collecting duct cells to increase water reabsorption and reduce urine output.
Desmopressin is a synthetic vasopressin analog that binds to V2 receptors on kidney collecting duct cells to increase water reabsorption and reduce urine output. Used for Central diabetes insipidus, Nocturnal enuresis, Von Willebrand disease.
At a glance
| Generic name | Desmopressin Injectable Solution |
|---|---|
| Also known as | DDAVP |
| Sponsor | Hamilton Health Sciences Corporation |
| Drug class | Vasopressin analog |
| Target | V2 receptor (vasopressin receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Desmopressin mimics the action of endogenous antidiuretic hormone (ADH/vasopressin) by selectively activating V2 receptors in the renal collecting ducts, promoting aquaporin-2 water channel insertion and increasing water reabsorption. This mechanism reduces polyuria and increases urine osmolality, making it effective for conditions characterized by insufficient endogenous ADH or impaired renal response to ADH.
Approved indications
- Central diabetes insipidus
- Nocturnal enuresis
- Von Willebrand disease
- Hemophilia A
Common side effects
- Hyponatremia
- Headache
- Nausea
- Abdominal pain
- Facial flushing
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome (PHASE2)
- Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (PHASE3)
- DDAVP Effect by TEG6 in Cardiac Surgery
- Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: